[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity
Form 4 Overview 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
Director Floyd F. Petersen disclosed the sale of 500 shares of Amphastar Pharmaceuticals common stock on 07 July 2025 (trade date 07/02/2025) at a weighted-average price of $23.4679 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 26 November 2024. Following the sale, Petersen鈥檚 direct ownership stands at 77,531 shares.
No derivative securities were involved and no other transactions were reported.
- Percentage of holdings sold: roughly 0.6 % of the director鈥檚 reported stake.
- The filing indicates continued direct ownership; no change to indirect holdings was reported.
- Rule 10b5-1 plan suggests the trade was scheduled in advance, reducing concerns over information asymmetry.
Given the modest size of the sale relative to total ownership and the use of a 10b5-1 plan, the market impact is likely limited.
Panoramica del Modulo 4 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
Il direttore Floyd F. Petersen ha comunicato la vendita di 500 azioni delle azioni ordinarie di Amphastar Pharmaceuticals in data 07 luglio 2025 (data di negoziazione 02/07/2025) a un prezzo medio ponderato di 23,4679 $ per azione. L鈥檕perazione 猫 stata eseguita nell鈥檃mbito di un piano di trading Rule 10b5-1 predefinito, adottato il 26 novembre 2024. Dopo la vendita, la propriet脿 diretta di Petersen 猫 pari a 77.531 azioni.
Non sono stati coinvolti strumenti derivati n茅 sono state segnalate altre transazioni.
- Percentuale delle azioni vendute: circa il 0,6% della partecipazione dichiarata dal direttore.
- La dichiarazione indica il mantenimento della propriet脿 diretta; non sono stati riportati cambiamenti nella propriet脿 indiretta.
- Il piano Rule 10b5-1 suggerisce che la transazione fosse programmata in anticipo, riducendo i rischi di asimmetria informativa.
Considerando la modesta dimensione della vendita rispetto alla propriet脿 totale e l鈥檜so del piano 10b5-1, l鈥檌mpatto sul mercato 猫 probabilmente limitato.
Resumen del Formulario 4 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
El director Floyd F. Petersen revel贸 la venta de 500 acciones comunes de Amphastar Pharmaceuticals el 07 de julio de 2025 (fecha de operaci贸n 02/07/2025) a un precio promedio ponderado de 23,4679 $ por acci贸n. La transacci贸n se realiz贸 bajo un plan de negociaci贸n Rule 10b5-1 preestablecido adoptado el 26 de noviembre de 2024. Tras la venta, la propiedad directa de Petersen es de 77,531 acciones.
No se involucraron valores derivados ni se reportaron otras transacciones.
- Porcentaje de participaciones vendidas: aproximadamente el 0,6% de la participaci贸n declarada del director.
- La presentaci贸n indica propiedad directa continua; no se reportaron cambios en la propiedad indirecta.
- El plan Rule 10b5-1 sugiere que la operaci贸n fue programada con anticipaci贸n, reduciendo preocupaciones sobre asimetr铆a de informaci贸n.
Dado el tama帽o modesto de la venta en relaci贸n con la propiedad total y el uso del plan 10b5-1, es probable que el impacto en el mercado sea limitado.
靹滌嫕 4 臧滌殧 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
鞚挫偓 Floyd F. Petersen电� 2025雲� 7鞗� 7鞚�鞐� Amphastar Pharmaceuticals 氤错喌欤� 500欤�毳� 欤茧嫻 韽夑窢 臧�欷� 臧�瓴� 23.4679雼煬鞐� 毵る弰頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟(瓯半灅鞚� 2025雲� 7鞗� 2鞚�). 鞚� 瓯半灅电� 2024雲� 11鞗� 26鞚� 毂勴儩霅� 靷爠 瓿勴殟霅� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞀惦媹雼�. 毵る弰 頉� Petersen鞚� 歆侅爲 靻岇湢 欤检嫕鞚� 77,531欤�鞛呺媹雼�.
韺岇儩 歃濌秾鞚� 韽暔霅橃 鞎婌晿鞙茧┌ 雼るジ 瓯半灅霃� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
- 毵る弰 歆�攵� 牍勳湪: 鞚挫偓臧� 氤搓碃頃� 歆�攵勳潣 鞎� 0.6%鞛呺媹雼�.
- 鞁犼碃靹滌棎电� 歆侅爲 靻岇湢甓岇澊 鞙犾霅潉 雮橅儉雮措┌ 臧勳爲 靻岇湢甓� 氤�瓴届潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
- Rule 10b5-1 瓿勴殟鞚� 瓯半灅臧� 靷爠鞐� 鞓堨爼霅橃棃鞚岇潉 鞁滌偓頃橃棳 鞝曤炒 牍勲寑旃� 鞖半牑毳� 欷勳瀰雼堧嫟.
鞝勳泊 靻岇湢甓� 雽�牍� 毵る弰 攴滊臧� 鞛戧碃 10b5-1 瓿勴殟鞚� 靷毄頄堨溂氙�搿� 鞁滌灔鞐� 氙胳箻电� 鞓來枼鞚� 鞝滍暅鞝侅澕 臧�電レ劚鞚� 雴掛姷雼堧嫟.
R茅sum茅 du Formulaire 4 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
Le directeur Floyd F. Petersen a d茅clar茅 la vente de 500 actions ordinaires d鈥橝mphastar Pharmaceuticals le 7 juillet 2025 (date de transaction 02/07/2025) 脿 un prix moyen pond茅r茅 de 23,4679 $ par action. La transaction a 茅t茅 r茅alis茅e dans le cadre d鈥檜n plan de n茅gociation Rule 10b5-1 pr茅茅tabli adopt茅 le 26 novembre 2024. Apr猫s la vente, la d茅tention directe de Petersen s鈥櫭﹍猫ve 脿 77 531 actions.
Aucun instrument d茅riv茅 n鈥檃 茅t茅 impliqu茅 et aucune autre transaction n鈥檃 茅t茅 signal茅e.
- Pourcentage des actions vendues : environ 0,6 % de la participation d茅clar茅e du directeur.
- Le d茅p么t indique une d茅tention directe continue ; aucun changement dans les participations indirectes n鈥檃 茅t茅 signal茅.
- Le plan Rule 10b5-1 sugg猫re que la transaction a 茅t茅 planifi茅e 脿 l鈥檃vance, r茅duisant les risques d鈥檃sym茅trie d鈥檌nformation.
Compte tenu de la taille modeste de la vente par rapport 脿 la d茅tention totale et de l鈥檜tilisation du plan 10b5-1, l鈥檌mpact sur le march茅 est probablement limit茅.
Formular 4 脺bersicht 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
Direktor Floyd F. Petersen meldete den Verkauf von 500 Aktien der Amphastar Pharmaceuticals Stammaktien am 07. Juli 2025 (Handelsdatum 02.07.2025) zu einem gewichteten Durchschnittspreis von 23,4679 $ pro Aktie. Die Transaktion wurde im Rahmen eines vorab vereinbarten Rule 10b5-1 Handelsplans durchgef眉hrt, der am 26. November 2024 angenommen wurde. Nach dem Verkauf h盲lt Petersen direkt 77.531 Aktien.
Es waren keine Derivate involviert und es wurden keine weiteren Transaktionen gemeldet.
- Verkaufter Anteil: etwa 0,6 % des gemeldeten Anteils des Direktors.
- Die Meldung zeigt weiterhin direkten Besitz; keine 脛nderungen bei indirekten Beteiligungen wurden gemeldet.
- Der Rule 10b5-1 Plan deutet darauf hin, dass der Handel im Voraus geplant war, was Bedenken hinsichtlich Informationsasymmetrien verringert.
Angesichts der vergleichsweise geringen Verkaufsgr枚脽e und der Nutzung des 10b5-1 Plans ist die Marktauswirkung wahrscheinlich begrenzt.
- Use of Rule 10b5-1 plan underscores strong compliance and reduces perception of opportunistic trading.
- Insider selling, albeit small, can be perceived as a mildly negative signal by some market participants.
Insights
TL;DR Small 500-share sale (~0.6 % of stake) via 10b5-1 plan; neutral-to-slightly negative signal with minimal impact.
The reported disposition is de minimis for a director holding more than 77 k shares. Use of a Rule 10b5-1 plan mitigates signalling risk because trades were pre-scheduled, but any insider sale can create mild negative sentiment, especially if clustered with other insider activity. No derivatives, no change to beneficial ownership structure, and no other insiders involved, so liquidity impact is negligible. Overall, I classify this event as neutral for valuation, with limited informational value for investors.
TL;DR Pre-planned trade shows compliance discipline; sale size immaterial鈥攊mpact neutral.
From a governance standpoint, adherence to Rule 10b5-1 demonstrates best practice and reduces litigation risk surrounding insider trading claims. The signature by power of attorney and precise disclosure of weighted-average pricing align with SEC guidance. The transaction does not materially alter the director鈥檚 ownership or influence. Accordingly, I view the disclosure as routine housekeeping rather than a directional signal.
Panoramica del Modulo 4 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
Il direttore Floyd F. Petersen ha comunicato la vendita di 500 azioni delle azioni ordinarie di Amphastar Pharmaceuticals in data 07 luglio 2025 (data di negoziazione 02/07/2025) a un prezzo medio ponderato di 23,4679 $ per azione. L鈥檕perazione 猫 stata eseguita nell鈥檃mbito di un piano di trading Rule 10b5-1 predefinito, adottato il 26 novembre 2024. Dopo la vendita, la propriet脿 diretta di Petersen 猫 pari a 77.531 azioni.
Non sono stati coinvolti strumenti derivati n茅 sono state segnalate altre transazioni.
- Percentuale delle azioni vendute: circa il 0,6% della partecipazione dichiarata dal direttore.
- La dichiarazione indica il mantenimento della propriet脿 diretta; non sono stati riportati cambiamenti nella propriet脿 indiretta.
- Il piano Rule 10b5-1 suggerisce che la transazione fosse programmata in anticipo, riducendo i rischi di asimmetria informativa.
Considerando la modesta dimensione della vendita rispetto alla propriet脿 totale e l鈥檜so del piano 10b5-1, l鈥檌mpatto sul mercato 猫 probabilmente limitato.
Resumen del Formulario 4 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
El director Floyd F. Petersen revel贸 la venta de 500 acciones comunes de Amphastar Pharmaceuticals el 07 de julio de 2025 (fecha de operaci贸n 02/07/2025) a un precio promedio ponderado de 23,4679 $ por acci贸n. La transacci贸n se realiz贸 bajo un plan de negociaci贸n Rule 10b5-1 preestablecido adoptado el 26 de noviembre de 2024. Tras la venta, la propiedad directa de Petersen es de 77,531 acciones.
No se involucraron valores derivados ni se reportaron otras transacciones.
- Porcentaje de participaciones vendidas: aproximadamente el 0,6% de la participaci贸n declarada del director.
- La presentaci贸n indica propiedad directa continua; no se reportaron cambios en la propiedad indirecta.
- El plan Rule 10b5-1 sugiere que la operaci贸n fue programada con anticipaci贸n, reduciendo preocupaciones sobre asimetr铆a de informaci贸n.
Dado el tama帽o modesto de la venta en relaci贸n con la propiedad total y el uso del plan 10b5-1, es probable que el impacto en el mercado sea limitado.
靹滌嫕 4 臧滌殧 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
鞚挫偓 Floyd F. Petersen电� 2025雲� 7鞗� 7鞚�鞐� Amphastar Pharmaceuticals 氤错喌欤� 500欤�毳� 欤茧嫻 韽夑窢 臧�欷� 臧�瓴� 23.4679雼煬鞐� 毵る弰頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟(瓯半灅鞚� 2025雲� 7鞗� 2鞚�). 鞚� 瓯半灅电� 2024雲� 11鞗� 26鞚� 毂勴儩霅� 靷爠 瓿勴殟霅� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞀惦媹雼�. 毵る弰 頉� Petersen鞚� 歆侅爲 靻岇湢 欤检嫕鞚� 77,531欤�鞛呺媹雼�.
韺岇儩 歃濌秾鞚� 韽暔霅橃 鞎婌晿鞙茧┌ 雼るジ 瓯半灅霃� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
- 毵る弰 歆�攵� 牍勳湪: 鞚挫偓臧� 氤搓碃頃� 歆�攵勳潣 鞎� 0.6%鞛呺媹雼�.
- 鞁犼碃靹滌棎电� 歆侅爲 靻岇湢甓岇澊 鞙犾霅潉 雮橅儉雮措┌ 臧勳爲 靻岇湢甓� 氤�瓴届潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
- Rule 10b5-1 瓿勴殟鞚� 瓯半灅臧� 靷爠鞐� 鞓堨爼霅橃棃鞚岇潉 鞁滌偓頃橃棳 鞝曤炒 牍勲寑旃� 鞖半牑毳� 欷勳瀰雼堧嫟.
鞝勳泊 靻岇湢甓� 雽�牍� 毵る弰 攴滊臧� 鞛戧碃 10b5-1 瓿勴殟鞚� 靷毄頄堨溂氙�搿� 鞁滌灔鞐� 氙胳箻电� 鞓來枼鞚� 鞝滍暅鞝侅澕 臧�電レ劚鞚� 雴掛姷雼堧嫟.
R茅sum茅 du Formulaire 4 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
Le directeur Floyd F. Petersen a d茅clar茅 la vente de 500 actions ordinaires d鈥橝mphastar Pharmaceuticals le 7 juillet 2025 (date de transaction 02/07/2025) 脿 un prix moyen pond茅r茅 de 23,4679 $ par action. La transaction a 茅t茅 r茅alis茅e dans le cadre d鈥檜n plan de n茅gociation Rule 10b5-1 pr茅茅tabli adopt茅 le 26 novembre 2024. Apr猫s la vente, la d茅tention directe de Petersen s鈥櫭﹍猫ve 脿 77 531 actions.
Aucun instrument d茅riv茅 n鈥檃 茅t茅 impliqu茅 et aucune autre transaction n鈥檃 茅t茅 signal茅e.
- Pourcentage des actions vendues : environ 0,6 % de la participation d茅clar茅e du directeur.
- Le d茅p么t indique une d茅tention directe continue ; aucun changement dans les participations indirectes n鈥檃 茅t茅 signal茅.
- Le plan Rule 10b5-1 sugg猫re que la transaction a 茅t茅 planifi茅e 脿 l鈥檃vance, r茅duisant les risques d鈥檃sym茅trie d鈥檌nformation.
Compte tenu de la taille modeste de la vente par rapport 脿 la d茅tention totale et de l鈥檜tilisation du plan 10b5-1, l鈥檌mpact sur le march茅 est probablement limit茅.
Formular 4 脺bersicht 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
Direktor Floyd F. Petersen meldete den Verkauf von 500 Aktien der Amphastar Pharmaceuticals Stammaktien am 07. Juli 2025 (Handelsdatum 02.07.2025) zu einem gewichteten Durchschnittspreis von 23,4679 $ pro Aktie. Die Transaktion wurde im Rahmen eines vorab vereinbarten Rule 10b5-1 Handelsplans durchgef眉hrt, der am 26. November 2024 angenommen wurde. Nach dem Verkauf h盲lt Petersen direkt 77.531 Aktien.
Es waren keine Derivate involviert und es wurden keine weiteren Transaktionen gemeldet.
- Verkaufter Anteil: etwa 0,6 % des gemeldeten Anteils des Direktors.
- Die Meldung zeigt weiterhin direkten Besitz; keine 脛nderungen bei indirekten Beteiligungen wurden gemeldet.
- Der Rule 10b5-1 Plan deutet darauf hin, dass der Handel im Voraus geplant war, was Bedenken hinsichtlich Informationsasymmetrien verringert.
Angesichts der vergleichsweise geringen Verkaufsgr枚脽e und der Nutzung des 10b5-1 Plans ist die Marktauswirkung wahrscheinlich begrenzt.
FAQ
How many Amphastar (AMPH) shares did Director Floyd Petersen sell?
What price did the AMPH shares trade at in the disclosed sale?
Does Petersen still own AMPH stock after the sale?
Was the sale made under a Rule 10b5-1 trading plan?
Is this insider sale considered material to Amphastar鈥檚 stock outlook?
